Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With Capecitabine in Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Eligibility Criteria~1. Histologic confirmation of adenocarcinoma of the rectum.~2. The lesion must be located in the rectum. For purposes of this study, the lesion must be within 12 cm of the anus as measured by sigmoidoscopy.~3. Patients must have indication of a locally advanced lesion defined for this study as tumor through the bowel wall (\> T3) or involving regional lymph nodes (\>N1). Clinical stage determination may be made by physical examination (for T4 lesions only), endoscopic ultrasound or CT scan of pelvis.~4. Patients with metastatic disease are eligible provided operative intervention on primary site is anticipated.~5. Patients must have adequate organ function defined as pretreatment leukocyte count \> 3,000/ul, platelet count \> 100,000/ul, serum creatinine \< 2.0 mg/dl, serum bilirubin \< 2 mg/dl. Note: Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance \< 30 ml/min). In patients with calculated creatinine clearance of 30-50 ml/min capecitabine will begin at (-)1 level dose reduction (see section 6.3)~6. Patients must be at least 18 years of age and have a Zubrod performance status of \< 2 (see appendix 1.)~7. Patients must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to the initiation of therapy.~Exclusion Criteria:~1. Patients may not have received previous pelvic irradiation for any indication, or previous chemotherapy for cancer therapy within the preceding 6 months.~2. Patients must have no other serious medical or psychiatric illness that would limit the ability of the patient to receive protocol therapy or provide informed consent.~3. Pregnant or lactating women may not participate. Women/men of reproductive potential must agree to use an effective contraceptive method.~4. Patients with lack of physical integrity of the upper gastrointestinal tract, inability to swallow tablets or those who have malabsorption syndrome are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).